Core Viewpoint - The announcement details a supplemental agreement between the buyer and seller regarding the payment terms of a sales agreement, specifically concerning the payment of 116 million RMB, which is approximately 123.64 million HKD at the specified exchange rate [1] Group 1 - The total sale price for the shares is set at 116 million RMB, which will be paid by the buyer through the issuance of shares to the sellers as outlined in Schedule I [1] - The buyer is required to ensure that the portable digital X-ray diagnostic robot system is successfully registered with the Zhejiang Provincial Food and Drug Administration and obtains the medical device registration certificate within 30 days post-closing [1] - The payment will be made in the form of 100% of the consideration shares allocated proportionally to each seller after the successful registration and within the specified timeframe [1]
泰凌医药：修订收购协议，支付人民币1.16亿元收购目标公司100%已发行股份